LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Spine/FzioMed Tries Again With FDA
Spine

FzioMed Tries Again With FDA

December 11, 2012 1 min read Premium comments

Advertisement

FzioMed Tries Again With FDA
Source: Courtesy of FzioMed
Secondary

Back in September 2008, FDA denied FzioMed, Inc.’s premarket approval application for its product Oxiplex Gel—an absorbable, clear, viscoelastic gel that some surgeons apply during lumbar spine surgery immediately prior to wound closure. FzioMed has now filed a petition for reconsideration with the FDA under Section 515(g)(2)(a) of the Food Drug Cosmetic Act, Section 562 of the FD&C act and Part 10.33 of Title 21 Code of Federal regulations.

Company officials maintain that, based on four studies involving more than 500 patients and nearly 10 years of commercial use benefitting more than 300, 000 patients outside the U.S., Oxiplex has proven itself to be an effective surgical adjuvant that significantly reduces the effects of failed back surgery syndrome (FBSS) such as leg pain and neurological symptoms. They note that their product is available in nearly 70 countries, including those in the European Union, Australia, Canada, Brazil, Mexico and South Korea. According to information supplied by FzioMed, the United States is the only country to deny an application for approval of Oxiplex.

Patients and spine surgeons across the United States are eager to take advantage of the safe, pain-relieving benefits of Oxiplex and hope the FDA will reconsider its decision to deny access to U.S. patients, ” said John Krelle, company president and CEO, in a December 3 press release. “FzioMed strongly believes that there are several significant issues of scientific dispute that warrant review by an independent advisory committee.

Krelle went on to say that there have not been any reports of safety issues associated with the device among more than 300, 000 surgical patients who have been treated with Oxiplex. He added that those surgical procedures occurred in countries whose regulatory agencies are science-based and equally as stringent as the U.S. FDA.

FzioMed is a privately held medical device company, founded in 1996, that develops, manufactures and commercializes absorbable surgical biomaterials based on its patented polymer science. Company officials report that FzioMed adhesion barriers are used in many surgical applications including spine, orthopedics, hand, tendon, peripheral nerve, gynecology and general surgery. Its spine gel is distributed by Medtronic, Inc., DePuy and other independent distributors.

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy